AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Neurogene Inc. Director's Dealing 2020

Mar 16, 2020

33497_dirs_2020-03-16_f1f42b15-927e-4c7a-a8a8-3b8846c63d47.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2020-03-16

Reporting Person: Ho Robert (Chief Financial Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3000	Direct